NASDAQ:GTHX - G1 Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$50.91 +2.60 (+5.38 %)
(As of 05/21/2018 06:24 AM ET)
Previous Close$48.31
Today's Range$48.74 - $52.76
52-Week Range$12.04 - $52.76
Volume264,300 shs
Average Volume212,231 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics logoG1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835

Debt

Debt-to-Equity RatioN/A
Current Ratio15.61
Quick Ratio15.61

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$520,000.00
Price / Sales3,201.46
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book15.47

Profitability

EPS (Most Recent Fiscal Year)($3.57)
Net Income$-60,120,000.00
Net MarginsN/A
Return on Equity-53.55%
Return on Assets-49.18%

Miscellaneous

Employees44
Outstanding Shares32,700,000

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics (NASDAQ:GTHX) announced its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.70) EPS for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.07. View G1 Therapeutics' Earnings History.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for G1 Therapeutics.

What price target have analysts set for GTHX?

5 brokerages have issued twelve-month price targets for G1 Therapeutics' stock. Their predictions range from $31.00 to $60.00. On average, they expect G1 Therapeutics' share price to reach $41.80 in the next year. View Analyst Ratings for G1 Therapeutics.

What are Wall Street analysts saying about G1 Therapeutics stock?

Here are some recent quotes from research analysts about G1 Therapeutics stock:
  • 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (5/15/2018)
  • 2. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
  • 3. Cowen Inc analysts commented, "G1 Therapeutics reported a Q3 net loss of $16MM and September 30 cash of." (11/8/2017)

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a decline in short interest during the month of April. As of April 13th, there was short interest totalling 1,241,765 shares, a decline of 32.8% from the March 30th total of 1,847,550 shares. Based on an average trading volume of 164,616 shares, the days-to-cover ratio is currently 7.5 days. Approximately 6.4% of the company's stock are short sold.

Who are some of G1 Therapeutics' key competitors?

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the folowing people:
  • Dr. Mark A. Velleca, CEO, Pres & Director (Age 54)
  • Dr. Rajesh K. Malik, Chief Medical Officer (Age 59)
  • Mr. Barclay A. Phillips, CFO & Sr. VP of Corp. Devel. (Age 55)
  • Ms. Jennifer K. Moses, VP of Fin. & Admin. & Principal Accounting Officer (Age 43)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Has G1 Therapeutics been receiving favorable news coverage?

News headlines about GTHX stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. G1 Therapeutics earned a daily sentiment score of 0.14 on Accern's scale. They also assigned headlines about the company an impact score of 46.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.00%), BlackRock Inc. (3.92%), Rock Springs Capital Management LP (0.88%), Point72 Asset Management L.P. (0.69%), JPMorgan Chase & Co. (0.68%) and Northern Trust Corp (0.48%). Company insiders that own G1 Therapeutics stock include Clay Thorp, Fredric N Eshelman, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp and Rajesh Malik. View Institutional Ownership Trends for G1 Therapeutics.

Which institutional investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Hodges Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have sold G1 Therapeutics company stock in the last year include Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc and Rajesh Malik. View Insider Buying and Selling for G1 Therapeutics.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Rock Springs Capital Management LP, Point72 Asset Management L.P., Birchview Capital LP, Swiss National Bank and Millennium Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $50.91.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $1.66 billion and generates $520,000.00 in revenue each year. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.


MarketBeat Community Rating for G1 Therapeutics (GTHX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

G1 Therapeutics (NASDAQ:GTHX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for G1 Therapeutics in the last 12 months. Their average twelve-month price target is $41.80, suggesting that the stock has a possible downside of 17.89%. The high price target for GTHX is $60.00 and the low price target for GTHX is $31.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.80$38.20$32.80$29.75
Price Target Upside: 17.89% downside7.45% upside42.79% upside33.41% upside

G1 Therapeutics (NASDAQ:GTHX) Consensus Price Target History

Price Target History for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $60.00HighView Rating Details
3/7/2018BTIG ResearchReiterated RatingBuy$48.00HighView Rating Details
3/6/2018JPMorgan ChaseReiterated RatingOverweight ➝ Overweight$33.00 ➝ $39.00HighView Rating Details
3/5/2018CowenReiterated RatingBuyLowView Rating Details
6/12/2017WedbushInitiated CoverageOutperform$31.00HighView Rating Details
(Data available from 5/21/2016 forward)

Earnings

G1 Therapeutics (NASDAQ:GTHX) Earnings History and Estimates Chart

Earnings by Quarter for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.56)($0.56)($0.56)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.61)($0.61)($0.61)

G1 Therapeutics (NASDAQ GTHX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.67)N/AView Earnings Details
5/3/2018Q1 2018($0.6280)($0.70)ViewN/AView Earnings Details
2/21/2018Q4 2017($0.58)($0.60)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.56)($0.55)ViewN/AView Earnings Details
8/9/20176/30/2017($0.61)($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

G1 Therapeutics (NASDAQ:GTHX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

G1 Therapeutics (NASDAQ GTHX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.92%
Institutional Ownership Percentage: 60.93%
Insider Trading History for G1 Therapeutics (NASDAQ:GTHX)
Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ GTHX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Mark A VellecaInsiderSell7,500$46.28$347,100.00View SEC Filing  
5/7/2018Jennifer K MosesVPSell750$45.00$33,750.00View SEC Filing  
4/16/2018Mark A VellecaInsiderSell7,500$36.00$270,000.00View SEC Filing  
4/5/2018Jennifer K MosesVPSell750$37.47$28,102.50View SEC Filing  
3/15/2018Rajesh MalikInsiderSell3,776$38.18$144,167.68View SEC Filing  
3/5/2018Jennifer K MosesVPSell750$26.55$19,912.50View SEC Filing  
2/15/2018Rajesh MalikInsiderSell3,776$20.00$75,520.00View SEC Filing  
2/5/2018Jennifer K MosesVPSell750$22.99$17,242.50View SEC Filing  
1/16/2018Rajesh MalikInsiderSell3,776$22.96$86,696.96View SEC Filing  
1/5/2018Jennifer K MosesVPSell750$19.96$14,970.00View SEC Filing  
12/18/2017Mark A VellecaInsiderSell7,500$20.01$150,075.00View SEC Filing  
12/15/2017Medimmune Ventures, Inc.Major ShareholderSell200,000$19.75$3,950,000.00View SEC Filing  
12/1/2017Medimmune Ventures, Inc.Major ShareholderSell133,906$19.75$2,644,643.50View SEC Filing  
11/20/2017Medimmune Ventures, Inc.Major ShareholderSell200,000$20.01$4,002,000.00View SEC Filing  
11/13/2017Fredric N EshelmanDirectorBuy250,000$19.73$4,932,500.00View SEC Filing  
5/22/2017Clay ThorpMajor ShareholderBuy133,333$15.00$1,999,995.00View SEC Filing  
5/22/2017Fredric N EshelmanDirectorBuy300,000$15.00$4,500,000.00View SEC Filing  
5/22/2017Ra Capital Healthcare Fund LpInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

G1 Therapeutics (NASDAQ GTHX) News Headlines

Source:
DateHeadline
G1 Therapeutics (GTHX) Price Target Increased to $60.00 by Analysts at Needham & Company LLCG1 Therapeutics (GTHX) Price Target Increased to $60.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - May 18 at 5:13 PM
G1 Therapeutics (GTHX) Given Consensus Recommendation of "Buy" by BrokeragesG1 Therapeutics (GTHX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 18 at 3:32 AM
This Day That Year: G1 TherapeuticsThis Day That Year: G1 Therapeutics
www.nasdaq.com - May 17 at 9:54 AM
G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingG1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 9:54 AM
G1 Therapeutics (GTHX) Insider Sells $347,100.00 in StockG1 Therapeutics (GTHX) Insider Sells $347,100.00 in Stock
www.americanbankingnews.com - May 16 at 4:20 PM
G1 Therapeutics (GTHX) Upgraded by Zacks Investment Research to "Hold"G1 Therapeutics (GTHX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 16 at 12:11 AM
-$0.62 Earnings Per Share Expected for G1 Therapeutics (GTHX) This Quarter-$0.62 Earnings Per Share Expected for G1 Therapeutics (GTHX) This Quarter
www.americanbankingnews.com - May 11 at 1:22 PM
G1 Therapeutics (GTHX) Lowered to Sell at Zacks Investment ResearchG1 Therapeutics (GTHX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:31 PM
G1 Therapeutics (GTHX) Upgraded by BidaskClub to "Strong-Buy"G1 Therapeutics (GTHX) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - May 9 at 6:39 PM
G1 Therapeutics (GTHX) VP Sells $33,750.00 in StockG1 Therapeutics (GTHX) VP Sells $33,750.00 in Stock
www.americanbankingnews.com - May 7 at 8:14 PM
G1 Therapeutics (GTHX) Posts Quarterly  Earnings Results, Misses Expectations By $0.07 EPSG1 Therapeutics (GTHX) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - May 4 at 6:14 PM
G1 Therapeutics (GTHX) CEO Mark Velleca on Q1 2018 Results - Earnings Call TranscriptG1 Therapeutics' (GTHX) CEO Mark Velleca on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 9:34 AM
Edited Transcript of GTHX.O earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of GTHX.O earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 9:34 AM
G1 Therapeutics (GTHX) Upgraded at ValuEngineG1 Therapeutics (GTHX) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 5:12 PM
G1 Therapeutics Provides First Quarter 2018 Corporate and Financial UpdateG1 Therapeutics Provides First Quarter 2018 Corporate and Financial Update
finance.yahoo.com - May 3 at 4:15 PM
G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018G1 Therapeutics to Present at UBS Global Healthcare Conference in May 2018
finance.yahoo.com - May 1 at 9:39 AM
Short Interest in G1 Therapeutics (GTHX) Declines By 32.8%Short Interest in G1 Therapeutics (GTHX) Declines By 32.8%
www.americanbankingnews.com - April 29 at 2:44 AM
G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018G1 Therapeutics to Provide First Quarter 2018 Corporate and Financial Update on May 3, 2018
finance.yahoo.com - April 26 at 9:27 AM
G1 Therapeutics (GTHX) Cut to Sell at Zacks Investment ResearchG1 Therapeutics (GTHX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 26 at 12:22 AM
 Brokerages Expect G1 Therapeutics (GTHX) to Post -$0.64 Earnings Per Share Brokerages Expect G1 Therapeutics (GTHX) to Post -$0.64 Earnings Per Share
www.americanbankingnews.com - April 24 at 1:14 AM
Mark A. Velleca Sells 7,500 Shares of G1 Therapeutics (GTHX) StockMark A. Velleca Sells 7,500 Shares of G1 Therapeutics (GTHX) Stock
www.americanbankingnews.com - April 17 at 1:23 PM
G1 Therapeutics initiates Phase 1b/2 clinical trial of G1T38 in combination with Tagrisso for EGFR-mutant NSCLCG1 Therapeutics initiates Phase 1b/2 clinical trial of G1T38 in combination with Tagrisso for EGFR-mutant NSCLC
seekingalpha.com - April 16 at 9:36 AM
G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitors Trilaciclib and G1T38 at the 2018
www.nasdaq.com - April 9 at 9:56 AM
G1 Therapeutics (GTHX) Stock Rating Lowered by Zacks Investment ResearchG1 Therapeutics (GTHX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:46 PM
 Brokerages Anticipate G1 Therapeutics (GTHX) Will Announce Earnings of -$0.64 Per Share Brokerages Anticipate G1 Therapeutics (GTHX) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 7 at 3:25 AM
Jennifer K. Moses Sells 750 Shares of G1 Therapeutics (GTHX) StockJennifer K. Moses Sells 750 Shares of G1 Therapeutics (GTHX) Stock
www.americanbankingnews.com - April 5 at 7:32 PM
G1 Therapeutics (GTHX) Upgraded by BidaskClub to "Hold"G1 Therapeutics (GTHX) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 30 at 10:36 PM
G1 Therapeutics (GTHX) Short Interest Up 71.8% in MarchG1 Therapeutics (GTHX) Short Interest Up 71.8% in March
www.americanbankingnews.com - March 30 at 3:38 AM
G1 Therapeutics (GTHX) Downgraded by BidaskClubG1 Therapeutics (GTHX) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 11:29 AM
G1 Therapeutics Inc (GTHX) Given Average Recommendation of "Buy" by AnalystsG1 Therapeutics Inc (GTHX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 29 at 3:13 AM
G1 Therapeutics (GTHX) Rating Increased to Buy at BidaskClubG1 Therapeutics (GTHX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
G1 Therapeutics (GTHX) Stock Rating Upgraded by Zacks Investment ResearchG1 Therapeutics (GTHX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 25 at 10:09 AM
G1 Therapeutics (GTHX) Raised to Hold at BidaskClubG1 Therapeutics (GTHX) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM
G1 Therapeutics Inc (GTHX) Expected to Post Earnings of -$0.64 Per ShareG1 Therapeutics Inc (GTHX) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - March 21 at 3:10 AM
G1 Therapeutics (GTHX) Upgraded to Strong-Buy at BidaskClubG1 Therapeutics (GTHX) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM
Rajesh Malik Sells 3,776 Shares of G1 Therapeutics Inc (GTHX) StockRajesh Malik Sells 3,776 Shares of G1 Therapeutics Inc (GTHX) Stock
www.americanbankingnews.com - March 16 at 1:20 PM
G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% HigherG1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher
finance.yahoo.com - March 14 at 10:45 AM
G1 Therapeutics (GTHX) Given New $42.00 Price Target at Needham & Company LLCG1 Therapeutics (GTHX) Given New $42.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - March 13 at 3:50 PM
G1 Therapeutics Announces Closing of Offering of Common StockG1 Therapeutics Announces Closing of Offering of Common Stock
finance.yahoo.com - March 12 at 5:19 PM
G1 Therapeutics (GTHX) Upgraded to Buy at BidaskClubG1 Therapeutics (GTHX) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - March 11 at 12:16 AM
Wedbush Equities Analysts Decrease Earnings Estimates for G1 Therapeutics Inc (GTHX)Wedbush Equities Analysts Decrease Earnings Estimates for G1 Therapeutics Inc (GTHX)
www.americanbankingnews.com - March 8 at 8:15 AM
G1 Therapeutics (GTHX) Given "Buy" Rating at BTIG ResearchG1 Therapeutics (GTHX) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - March 7 at 12:44 PM
G1 Therapeutics (GTHX) Commences 3M Share Offering of Common StockG1 Therapeutics (GTHX) Commences 3M Share Offering of Common Stock
www.streetinsider.com - March 7 at 9:47 AM
Insider Selling: G1 Therapeutics Inc (GTHX) VP Sells 750 Shares of StockInsider Selling: G1 Therapeutics Inc (GTHX) VP Sells 750 Shares of Stock
www.americanbankingnews.com - March 6 at 7:32 PM
JPMorgan Chase & Co. Increases G1 Therapeutics (GTHX) Price Target to $39.00JPMorgan Chase & Co. Increases G1 Therapeutics (GTHX) Price Target to $39.00
www.americanbankingnews.com - March 6 at 10:56 AM
G1 Therapeutics (GTHX) Reports Positive Trilaciclib Phase 2a Topline DataG1 Therapeutics (GTHX) Reports Positive Trilaciclib Phase 2a Topline Data
www.streetinsider.com - March 6 at 9:32 AM
G1 sees stock bump on big data readoutG1 sees stock bump on big data readout
finance.yahoo.com - March 5 at 4:50 PM
G1 Therapeutics Announces Proposed Offering of Common StockG1 Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - March 5 at 4:50 PM
G1 Therapeutics (GTHX) Rating Reiterated by CowenG1 Therapeutics (GTHX) Rating Reiterated by Cowen
www.americanbankingnews.com - March 5 at 4:30 PM
Active-Investors: Wired News - FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic CancerActive-Investors: Wired News - FDA Granted Fast Track Designation to FibroGen's Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer
www.finanznachrichten.de - March 5 at 9:58 AM

SEC Filings

G1 Therapeutics (NASDAQ:GTHX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

G1 Therapeutics (NASDAQ:GTHX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

G1 Therapeutics (NASDAQ GTHX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.